Loading
companiesCompany
Boston Scientific
Medical device giant whose TheraSphere glass microspheres deliver yttrium-90 radioembolisation in liver cancer.
Overview
Boston Scientific, based in Marlborough, Massachusetts, and listed as BSX, is the medical device company whose TheraSphere glass microspheres deliver yttrium-90 radioembolisation in liver cancer. TheraSphere has held FDA approval for hepatocellular carcinoma since 2021, was studied in the EPOCH trial in colorectal liver metastases, which was positive for progression-free survival, and is being tested in combination with immunotherapy, and the company also sells drug-eluting embolic beads and other interventional oncology devices. OnCo links it to hepatocellular carcinoma and colorectal cancer and to the radioembolisation and transarterial chemoembolisation technology records. Whether device-based liver-directed therapy keeps its role as systemic options improve is the open question. The technology pages carry the trial detail.
Similar pages
- TechnologyPartial nephrectomy, ablation & active surveillance of small renal masses
Shares Cryoablation systems, Devices and physical therapies roadmap: heat and light → electric fields and focused sound → drug-releasing implants, Thermal ablation (RFA, microwave, cryo).
- CompanySirtex Medical
Shares Radioembolisation (TARE / SIRT, yttrium-90), Hepatocellular carcinoma, Colorectal cancer.
- CompanyIceCure Medical
Shares Cryoablation systems, Thermal ablation (RFA, microwave, cryo).
- TechnologyMicrowave and radiofrequency ablation systems
Shares Cryoablation systems, Endoscopic ultrasound and EBUS systems, Thermal ablation (RFA, microwave, cryo), Hepatocellular carcinoma.
- CompanyQuantum Surgical
Shares Thermal ablation (RFA, microwave, cryo), Hepatocellular carcinoma, Colorectal cancer.
- TrialSARAH and SIRveNIB
Shares Radioembolisation (TARE / SIRT, yttrium-90), Hepatocellular carcinoma.
- TrialA Study of PTX-9908 Injection for Non-resectable HCC with TACE
Shares Transarterial chemoembolisation (TACE), Hepatocellular carcinoma.
- TrialA Phase II/III Trial Comparing Transarterial Tirapazamine Embolization (TATE) With cTACE for Intermediate-stage Liver Cancer.
Shares Transarterial chemoembolisation (TACE), Hepatocellular carcinoma.